Arsenal Biosciences

Arsenal Biosciences is a private, clinical-stage biotechnology company founded in 2019 and headquartered in South San Francisco, California. The company is developing next-generation, programmable T cell therapies for solid tumors, leveraging a proprietary technology platform that integrates synthetic biology and computational tools. ArsenalBio has established a strategic multi-program collaboration with Bristol Myers Squibb and is advancing a wholly owned pipeline, with its lead candidate, AB-3028 for prostate cancer, anticipated to enter First-in-Human trials in the first half of 2026. The company is led by a seasoned team with deep expertise in cell therapy, oncology, and company building.

A programmable and computationally driven platform to engineer T cells with multiple coordinated synthetic drug functions for the treatment of solid tumors.

ArsenalBio competes in the rapidly evolving field of next-generation cell therapies for solid tumors, facing competition from both large pharmaceutical companies (e.g., Novartis, Gilead, BMS) and numerous biotechnology firms (e.g., Adaptimmune, TCR2 Therapeutics, Instil Bio). Differentiation hinges on the sophistication and clinical success of its programmable, multi-functional platform.